Innovating Works
TAM-ADaCT: A Novel Antibody-Drug Conjugate for Targeting Tumor-Associated Macrophages in Solid Tumors ZELULA BIOPHARMA tramitó un HORIZON EUROPE: ERC-2023-POC "The project is focused on the development of a groundbreaking Antibody-Drug Conjugate (ADC) specifically designed for macrophage depletion...
2024-02-07 - 2025-08-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.